Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gout: HELP
Articles from California
Based on 142 articles published since 2008
||||

These are the 142 published articles about Gout that originated from California during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Editorial PPARGC1B: insight into the expression of the gouty inflammation phenotype: PPARGC1B and gouty inflammation. 2017

Merriman, Tony / Terkeltaub, Robert. ·Department of Biochemistry, University of Otago, Dunedin, New Zealand. · VA San Diego Healthcare System. · Department of Medicine, University of California San Diego, San Diego, CA, USA. ·Rheumatology (Oxford) · Pubmed #28003496.

ABSTRACT: -- No abstract --

2 Editorial Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. 2017

FitzGerald, John D / Neogi, Tuhina / Choi, Hyon K. ·University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ·Arthritis Rheumatol · Pubmed #28002890.

ABSTRACT: -- No abstract --

3 Editorial Emerging uricosurics for gout. 2017

Terkeltaub, Robert. ·a Department of Medicine, VA San Diego Healthcare System , University of California San Diego , La Jolla , CA , USA. ·Expert Rev Clin Pharmacol · Pubmed #27937050.

ABSTRACT: -- No abstract --

4 Editorial Good Intentions, Unintended Consequences, and Unrealized Benefits. 2015

FitzGerald, John D. ·David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Rehabilitation Center, University of California at Los Angeles, Room 32-59, Los Angeles, CA, 90095-1670, USA. JFitzgerald@mednet.ucla.edu. ·J Gen Intern Med · Pubmed #26239629.

ABSTRACT: -- No abstract --

5 Editorial Editorial: Can GPR43 Sensing of Short-Chain Fatty Acids Unchain Inflammasome-Driven Arthritis? 2015

Haslberger, Alexander / Terkeltaub, Robert. ·University of Vienna, Vienna, Austria. · VA San Diego Healthcare System, San Diego, California, and University of California at San Diego, La Jolla, California. ·Arthritis Rheumatol · Pubmed #25914362.

ABSTRACT: -- No abstract --

6 Editorial Gout and crystal arthropathies. 2014

Weisman, Michael H. ·Division of Rheumatology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90024, USA. Electronic address: michael.weisman@cshs.org. ·Rheum Dis Clin North Am · Pubmed #24703354.

ABSTRACT: -- No abstract --

7 Review Joint Clinical Consensus Statement of the American College of Foot and Ankle Surgeons® and the American Association of Nurse Practitioners®: Etiology, Diagnosis, and Treatment Consensus for Gouty Arthritis of the Foot and Ankle. 2018

Mirmiran, Roya / Bush, Tom / Cerra, Michele M / Grambart, Sean / Kauschinger, Elaine / Younger, Melissa / Zychowicz, Michael. ·Foot and Ankle Surgeon, Department of Surgery, Sutter Medical Group, Sacramento, CA. Electronic address: Roya.Mirmiran@aol.com. · Associate Professor and Assistant Dean for Practice, University of North Carolina at Chapel Hill Schools of Nursing and Medicine, Chapel Hill, NC. · Director of the Duke NP/PA Rheumatology Fellowship Program & Faculty, Department of Medicine, Duke University School of Medicine, NC. · Foot and Ankle Surgeon, Carle Physician Group, Department of Surgery, Champaign, IL. · Clinical Assistant Professor, Duke University School of Nursing, Durham, NC. · Podiatric Research Fellow, Penn Presbyterian Medical Center, Philadelphia, PA. · Professor and Director of MSN Program & Lead Faculty in Orthopedic NP Specialty, Duke University School of Nursing, Durham, NC. ·J Foot Ankle Surg · Pubmed #30368431.

ABSTRACT: Gout is a condition that commonly affects the foot and ankle, and practitioners who treat these structures should be aware of the methods to diagnose and treat this form of arthritis. Practitioners also need to recognize extra-articular manifestations of the disease. Although the acutely red, hot, swollen joint is a common presentation, chronic tophaceous gout can be associated with pain, nodule formation, and cutaneous compromise. Since the underlying causes that lead to excessive monosodium urate deposition may be treatable, early and accurate diagnosis can be very beneficial and may even prevent articular degeneration.

8 Review Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. 2018

Wallace, Mary C / Roberts, Rebecca L / Nanavati, Payal / Miner, Jeffrey N / Dalbeth, Nicola / Topless, Ruth / Merriman, Tony R / Stamp, Lisa K. ·Department of Surgical Sciences, University of Otago, Dunedin, New Zealand. · Biology Department, Ardea Biosciences, Inc., San Diego, CA, USA. · Department of Medicine, University of Auckland, Auckland, New Zealand. · Department of Biochemistry, University of Otago, Dunedin, New Zealand. · Department of Medicine, University of Otago, Christchurch, New Zealand. ·Rheumatology (Oxford) · Pubmed #29342288.

ABSTRACT: Objective: ABCG2 rs2231142 (Q141K) has been reported to be associated with poor response to allopurinol, while there are conflicting data on the association between the genetically independent ABCG2 rs10011796 variant and allopurinol response. The aim of this study was to replicate the association of ABCG2 rs2231142 and rs10011796 with allopurinol response and perform a meta-analysis. Methods: Participants in the Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) (n = 299) were studied. In patients with evidence of adherence to allopurinol therapy (plasma oxypurinol >20 μmol/l), good response was defined as serum urate <6 mg/dl on allopurinol ⩽300 mg/day and poor response as serum urate ⩾ 6 mg/dl despite allopurinol >300 mg/day. Association of rs2231142 and rs10011796 with poor response was tested in logistic regression models that included age, sex, BMI, ethnicity and estimated glomerular filtration rate. Results from the LASSO study and a subset of participants in the Genetics of Gout in Aotearoa New Zealand study (n = 296, including 264 from a previously published report) were combined by meta-analysis. Results: There was evidence for association of rs2231142 with allopurinol response [odds ratio (OR) = 2.35, P = 7.3 × 10-4] but not for rs10011796 (OR = 1.21, P = 0.33) in the LASSO cohort using an adjusted logistic regression model. Meta-analysis provided evidence of a significant association of rs2231142 with allopurinol response (OR = 2.43, P = 6.2 × 10-7), but not rs10011796 (OR = 1.06, P = 0.69). Conclusion: This study has confirmed the significant association of ABCG2 rs2231142 with poor response to allopurinol.

9 Review What makes gouty inflammation so variable? 2017

Terkeltaub, Robert. ·VA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. rterkeltaub@ucsd.edu. · Department of Medicine, University of California San Diego, San Diego, CA, USA. rterkeltaub@ucsd.edu. ·BMC Med · Pubmed #28818081.

ABSTRACT: Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem. Flares can be complex and expensive to treat, partly due to the frequent comorbidities. Unmet needs in gout management are more pressing given the markedly increasing gout flare hospital admission rates. In addition, chronic gouty arthritis can cause joint damage and functional impairment. This review addresses new knowledge on the basis for the marked, inherent variability of responses to deposited urate crystals, including the unpredictable and self-limited aspects of many gout flares. Specific topics reviewed include how innate immunity and two-signal inflammasome activation intersect with diet, metabolism, nutritional biosensing, the microbiome, and the phagocyte cytoskeleton and cell fate. The paper discusses the roles of endogenous constitutive regulators of inflammation, including certain nutritional biosensors, and emerging genetic and epigenetic factors. Recent advances in the basis of variability in responses to urate crystals in gout provide information about inflammatory arthritis, and have identified potential new targets and strategies for anti-inflammatory prevention and treatment of gouty arthritis.

10 Review Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). 2017

Dalbeth, Nicola / Bardin, Thomas / Doherty, Michael / Lioté, Frédéric / Richette, Pascal / Saag, Kenneth G / So, Alexander K / Stamp, Lisa K / Choi, Hyon K / Terkeltaub, Robert. ·Department of Medicine, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand. · University Paris Diderot Cité Sorbonne, Service de Rhumatologie, Centre Viggo Petersen, Lariboisière Hospital, INSERM U1132, Paris, France. · Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK. · Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (UAB), 820 Faculty Office Tower, 510 20th Street, Birmingham, Alabama 35294-3408, USA. · Service of Rheumatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Avenue Pierre Decker 4, 1011 Lausanne, Switzerland. · Department of Medicine, University of Otago, Christchurch, P.O. BOX 4345, Christchurch 8140, New Zealand. · Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, 55 Fruit Street, Harvard Medical School, Boston, Massachusetts 02114, USA. · VA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, California 92161, USA. ·Nat Rev Rheumatol · Pubmed #28794514.

ABSTRACT: In November 2016, the American College of Physicians (ACP) published a clinical practice guideline on the management of acute and recurrent gout. This guideline differs substantially from the latest guidelines generated by the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR) and 3e (Evidence, Expertise, Exchange) Initiative, despite reviewing largely the same body of evidence. The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) convened an expert panel to review the methodology and conclusions of these four sets of guidelines and examine possible reasons for discordance between them. The G-CAN position, presented here, is that the fundamental pathophysiological knowledge underlying gout care, and evidence from clinical experience and clinical trials, supports a treat-to-target approach for gout aimed at lowering serum urate levels to below the saturation threshold at which monosodium urate crystals form. This practice, which is truly evidence-based and promotes the steady reduction in tissue urate crystal deposits, is promoted by the ACR, EULAR and 3e Initiative recommendations. By contrast, the ACP does not provide a clear recommendation for urate-lowering therapy (ULT) for patients with frequent, recurrent flares or those with tophi, nor does it recommend monitoring serum urate levels of patients prescribed ULT. Results from emerging clinical trials that have gout symptoms as the primary end point are expected to resolve this debate for all clinicians in the near term future.

11 Review Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. 2017

Li, Xue / Meng, Xiangrui / Timofeeva, Maria / Tzoulaki, Ioanna / Tsilidis, Konstantinos K / Ioannidis, John PA / Campbell, Harry / Theodoratou, Evropi. ·Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH8 9AG, UK. · Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. · Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. · Stanford Prevention Research Center, Stanford School of Medicine, Stanford, CA, USA. · Department of Health Research and Policy, Stanford School of Medicine, Stanford, CA, USA. · Department of Statistics, Stanford University, Stanford, CA, USA. · Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH8 9AG, UK E.Theodoratou@ed.ac.uk. ·BMJ · Pubmed #28592419.

ABSTRACT:

12 Review Managing kidney transplant recipients in primary care. 2017

Roth, Shira. ·Shira Roth practices general nephrology at Stanford University Hospital in Stanford, Calif., after completing a fellowship in abdominal organ transplant at Mayo Clinic in Phoenix, Ariz. The author has disclosed no potential conflicts of interest, financial or otherwise. ·JAAPA · Pubmed #28538426.

ABSTRACT: Patients who have undergone kidney transplant are at increased risk for heart disease, new-onset diabetes, metabolic syndrome, and certain malignancies, in addition to opportunistic infections associated with immunosuppression. This article describes guidelines for routine management of kidney transplant recipients in primary care, as well as how to recognize risk factors and complications.

13 Review Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. 2017

Newberry, Sydne J / FitzGerald, John D / Motala, Aneesa / Booth, Marika / Maglione, Margaret A / Han, Dan / Tariq, Abdul / O'Hanlon, Claire E / Shanman, Roberta / Dudley, Whitney / Shekelle, Paul G. ·From RAND Corporation, Santa Monica, and David Geffen School of Medicine at the University of California and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California. ·Ann Intern Med · Pubmed #27802505.

ABSTRACT: Background: Alternative strategies exist for diagnosing gout that do not rely solely on the documentation of monosodium urate (MSU) crystals. Purpose: To summarize evidence regarding the accuracy of clinical tests and classification algorithms compared with that of a reference standard of MSU crystals in joint aspirate for diagnosing gout. Data Sources: Several electronic databases from inception to 29 February 2016. Study Selection: 21 prospective cohort, cross-sectional, and case-control studies including participants with joint inflammation and no previous definitive gout diagnosis who had MSU analysis of joint aspirate. Data Extraction: Data extraction and risk-of-bias assessment by 2 reviewers independently; overall strength of evidence (SOE) judgment by group. Data Synthesis: Recently developed algorithms including clinical, laboratory, and imaging criteria demonstrated good sensitivity (up to 88%) and fair to good specificity (up to 96%) for diagnosing gout (moderate SOE). Three studies of dual-energy computed tomography (DECT) showed sensitivities of 85% to 100% and specificities of 83% to 92% for diagnosing gout (low SOE). Six studies of ultrasonography showed sensitivities of 37% to 100% and specificities of 68% to 97%, depending on the ultrasonography signs assessed (pooled sensitivity and specificity for the double contour sign: 74% [95% CI, 52% to 88%] and 88% [CI, 68% to 96%], respectively [low SOE]). Limitation: Important study heterogeneity and selection bias; scant evidence in primary and urgent care settings and in patients with conditions that may be confused with or occur with gout. Conclusion: Multidimensional algorithms, which must be validated in primary and urgent care settings, may help clinicians make a provisional diagnosis of gout. Although DECT and ultrasonography also show promise for gout diagnosis, accessibility to these methods may be limited. Primary Funding Source: Agency for Healthcare Research and Quality. (Protocol registration: https://effectivehealthcare.ahrq.gov/ehc/products/564/1937/gout-protocol-140716.pdf).

14 Review Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. 2017

Shekelle, Paul G / Newberry, Sydne J / FitzGerald, John D / Motala, Aneesa / O'Hanlon, Claire E / Tariq, Abdul / Okunogbe, Adeyemi / Han, Dan / Shanman, Roberta. ·From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California. ·Ann Intern Med · Pubmed #27802478.

ABSTRACT: Background: Gout is a common type of inflammatory arthritis in patients seen by primary care physicians. Purpose: To review evidence about treatment of acute gout attacks, management of hyperuricemia to prevent attacks, and discontinuation of medications for chronic gout in adults. Data Sources: Multiple electronic databases from January 2010 to March 2016, reference mining, and pharmaceutical manufacturers. Study Selection: Studies of drugs approved by the U.S. Food and Drug Administration and commonly prescribed by primary care physicians, randomized trials for effectiveness, and trials and observational studies for adverse events. Data Extraction: Data extraction was performed by one reviewer and checked by a second reviewer. Study quality was assessed by 2 independent reviewers. Strength-of-evidence assessment was done by group discussion. Data Synthesis: High-strength evidence from 28 trials (only 3 of which were placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout. Moderate-strength evidence suggests that low-dose colchicine is as effective as high-dose colchicine and causes fewer gastrointestinal adverse events. Moderate-strength evidence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attacks after 1 year or more. High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting urate-lowering therapy, and moderate-strength evidence indicates that duration of prophylaxis should be longer than 8 weeks. Although lower urate levels reduce risk for recurrent acute attacks, treatment to a specific target level has not been tested. Limitation: Few studies of acute gout treatments, no placebo-controlled trials of management of hyperuricemia lasting longer than 6 months, and few studies in primary care populations. Conclusion: Colchicine, NSAIDs, and corticosteroids relieve pain in adults with acute gout. Urate-lowering therapy decreases serum urate levels and reduces risk for acute gout attacks. Primary Funding Source: Agency for Healthcare Research and Quality. (Protocol registration: http://effectivehealth-care.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf).

15 Review Review: Gout: A Roadmap to Approaches for Improving Global Outcomes. 2017

Dalbeth, Nicola / Choi, Hyon K / Terkeltaub, Robert. ·University of Auckland, Auckland, New Zealand. · Massachusetts General Hospital and Harvard Medical School, Boston. · VA San Diego Healthcare System and University of California, San Diego. ·Arthritis Rheumatol · Pubmed #27389665.

ABSTRACT: -- No abstract --

16 Review Urate Handling in the Human Body. 2016

Hyndman, David / Liu, Sha / Miner, Jeffrey N. ·Ardea Biosciences, Inc., Biology Department, 9390 Towne Centre Drive, San Diego, CA, 92121, USA. DHyndman@ardeabio.com. · Ardea Biosciences, Inc., Biology Department, 9390 Towne Centre Drive, San Diego, CA, 92121, USA. ·Curr Rheumatol Rep · Pubmed #27105641.

ABSTRACT: Elevated serum urate concentration is the primary cause of gout. Understanding the processes that affect serum urate concentration is important for understanding the etiology of gout and thereby understanding treatment. Urate handing in the human body is a complex system including three major processes: production, renal elimination, and intestinal elimination. A change in any one of these can affect both the steady-state serum urate concentration as well as other urate processes. The remarkable complexity underlying urate regulation and its maintenance at high levels in humans suggests that this molecule could potentially play an interesting role other than as a mere waste product to be eliminated as rapidly as possible.

17 Review Evolution of management of gout: a comparison of recent guidelines. 2015

Khanna, Puja P / FitzGerald, John. ·aDivision of Rheumatology, University of Michigan, Ann Arbor, Michigan bDavid Geffen School of Medicine, UCLA, Los Angeles, California, USA. ·Curr Opin Rheumatol · Pubmed #25611299.

ABSTRACT: PURPOSE OF REVIEW: There have been several guidelines on the management of gout over the last decade; however, inconsistencies between them create confusion for practitioners. This review highlights areas of agreement between guidelines and discusses data where disagreements exist. RECENT FINDINGS: For acute gout, the guidelines agree that anti-inflammatory treatment should start as soon as possible, preferably within 24 hours. Older guidelines preferred NSAIDs or colchicine over steroids, but newer ones leave the choice of agent to the physician. For colchicine, all guidelines recommend using low dose. Intra-articular, oral or intramuscular steroids are all described as effective. For management of hyperuricemia, indications for initiating urate-lowering therapy (ULT) have become more inclusive over the years by requiring lower burden of disease severity or including patient comorbidities. Probenecid has fallen out of favour with most guidelines favouring allopurinol over febuxostat. Although there is a disagreement about timing of initiation for ULT, guidelines recommend treating to target of serum urate (sUA) less than 6 mg/dl, and less than 5 mg/dl for patients with more severe disease. Concurrent anti-inflammatory prophylaxis has gained strong support over the years. SUMMARY: Most guidelines are in agreement with recommendations for management of gout and most changes have been directional and evolutionary.

18 Review Management of primary care issues common to CKD and ESRD patients: a brief primer for the nephrology provider. 2014

Chettiar, Alexis. ·1850 Mountain Boulevard, Oakland, CA. Electronic address: alexis.chettiar@yahoo.com. ·Adv Chronic Kidney Dis · Pubmed #24969390.

ABSTRACT: This article provides a brief overview of the diagnosis and management of selected primary care issues that are common to CKD and ESRD patients. The elements of diagnosis and management unique to kidney patients and controversies and updates in management will be presented. The topics reviewed are neuropathy, pruritus, zoster, hyperuricemia, gout, and gastroparesis.

19 Review Multiple firm nodules and tender, indurated plaques. 2014

Olazagasti, Jeannette / Wang, Audrey S / Isseroff, Rivkah. ·School of Medicine, University of Puerto Rico, San Juan, Puerto Rico. · University of California, Davis, Sacramento. ·JAMA Dermatol · Pubmed #24671726.

ABSTRACT: -- No abstract --

20 Review Treatment of acute gout: a systematic review. 2014

Khanna, Puja P / Gladue, Heather S / Singh, Manjit K / FitzGerald, John D / Bae, Sangmee / Prakash, Shraddha / Kaldas, Marian / Gogia, Maneesh / Berrocal, Veronica / Townsend, Whitney / Terkeltaub, Robert / Khanna, Dinesh. ·Division of Rheumatology, University of Michigan, 300 North Ingalls, 7D13, Ann Arbor, MI 48109-5422. Electronic address: pkhanna@umich.edu. · Emory University, Atlanta, GA. · Rochester General Health System, Rochester, NY. · David Geffen School of Medicine, UCLA, Los Angeles, CA. · Division of Rheumatology, University of Michigan, 300 North Ingalls, 7D13, Ann Arbor, MI 48109-5422. · Division of Rheumatology, University of Michigan, 300 North Ingalls, 7D13, Ann Arbor, MI 48109-5422; Taubman Health Science Library, University of Michigan, 300 North Ingalls, 7D13, Ann Arbor, MI 48109-5422. · VAMC/UCSD, La Jolla, CA. ·Semin Arthritis Rheum · Pubmed #24650777.

ABSTRACT: OBJECTIVE: Acute gout is traditionally treated with NSAIDs, corticosteroids, and colchicine; however, subjects have multiple comorbidities that limit the use of some conventional therapies. We systematically reviewed the published data on the pharmacologic and non-pharmacologic agents used for the treatment of acute gouty arthritis. METHODS: A systematic search was performed using PubMed and Cochrane database through May 2013. We included only randomized controlled trials (RCTs) that included NSAIDs, corticosteroids, colchicine, adrenocorticotropic hormone (ACTH), interleukin-1 (IL-1) inhibitors, topical ice, or herbal supplements. RESULTS: Thirty articles were selected for systematic review. The results show that NSAIDs and COX-2 inhibitors are effective agents for the treatment of acute gout attacks. Systemic corticosteroids have similar efficacy to therapeutic doses of NSAIDs, with studies supporting oral and intramuscular use. ACTH is suggested to be efficacious in acute gout. Oral colchicine demonstrated to be effective, with low-dose colchicine demonstrating a comparable tolerability profile as placebo and a significantly lower side effect profile to high-dose colchicine. The IL-1β inhibitory antibody, canakinumab, was effective for the treatment of acute attacks in subjects refractory to and in those with contraindications to NSAIDs and/or colchicine. However, rilonacept was demonstrated to be not as effective, and there are no RCTs for the use of anakinra. CONCLUSION: NSAIDs, COX-2 selective inhibitors, corticosteroids, colchicine, ACTH, and canakinumab have evidence to suggest efficacy in treatment of acute gout.

21 Review Gout and the heart. 2014

Bhole, Vidula / Krishnan, Eswar. ·515 Olmsted Road, Palo Alto, CA 94305, USA. ·Rheum Dis Clin North Am · Pubmed #24268013.

ABSTRACT: The association between gout and cardiovascular diseases has been noted for centuries but was not subjected to rigorous epidemiologic studies until recently. The published literature is almost unanimous in the strength and consistency of this association. However, the impact of gout over and above that conferred by hyperuricemia and other risk factors of cardiovascular disease has not been well studied. Future studies are expected to shed light on the pathophysiologic basis of this association.

22 Review Filipino gout: a review. 2014

Prasad, Pooja / Krishnan, Eswar. ·Stanford University School of Medicine, Palo Alto, California. ·Arthritis Care Res (Hoboken) · Pubmed #23983155.

ABSTRACT: -- No abstract --

23 Review The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. 2012

Torralba, Karina D / De Jesus, Emerson / Rachabattula, Shylaja. ·Division of Rheumatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ktorralb@usc.edu ·Int J Rheum Dis · Pubmed #23253231.

ABSTRACT: Diet plays a significant role in the development of gout and hyperuricemia. Gout and hyperuricemia have likewise been associated with the development of cardiovascular disease and metabolic syndrome. Epidemiological studies have shown that certain foods influence levels of serum uric acid and the risk for development of gout.This article reviews the influence of dietary factors on serum uric acid levels and risk of gout, as well as the role of urate transporters in the development of hyperuricemia and gout.Various epidemiological studies have shown the effects of certain foods on the risk of developing gout and hyperuricemia. Low-fat dairy products, purine-rich vegetables, whole grains, nuts and legumes, and less sugary fruits, coffee and vitamin C supplements decrease the risk, whereas intake of red meat, fructose-containing beverages and alcohol increase the risk of gout. There is also an increased although basic understanding of the effects of vitamin C, alcohol and fructose on urate transporters. Certain foods can lead to a decreased or increased risk of development of gout and hyperuricemia. Advances have established the interplay of certain foods on urate transporters and renal handling of urate. More studies, especially prospective ones, are needed to increase our understanding of the roles of foods and urate transporters and other molecular mechanisms on the risk of developing gout and hyperuricemia.

24 Review Soyfoods, hyperuricemia and gout: a review of the epidemiologic and clinical data. 2011

Messina, Mark / Messina, Virginia L / Chan, Pauline. ·Department of Nutrition, School of Public Health, Loma Linda University and Nutrition Matters, Port Townsend, WA 98368, United States. markjohnmessina@gmail.com ·Asia Pac J Clin Nutr · Pubmed #21859653.

ABSTRACT: Soyfoods have long been a part of traditional Asian diets; they provide plentiful amounts of high-quality protein and have a favourable fatty acid profile. In addition, provocative research suggests soyfoods offer health benefits independent of the nutrients they provide. However, there is a widely-held belief among Asian health professionals and the public that soyfoods increase risk of gout and potentially precipitate acute attacks in patients with this disease. To examine the veracity of this belief, this review critically evaluated the relevant clinical and epidemiologic data. In addition, background information on the etiology and prevalence of hyperuricemia and gout in Asia is provided along with the results of a small survey of Asian healthcare professionals about their attitudes toward soyfoods. Among the healthcare professionals who responded to the survey, 95% considered soyfoods to be somewhat or very healthy and nutritious. In contrast, 48% expressed the view that soyfoods are likely to cause gout. However, none of the six epidemiologic studies identified provided any evidence that soy intake was associated with circulating uric acid levels, hyperuricemia or gout. Data from the five human intervention studies evaluated indicate soy protein does elevate serum uric levels, but in response to amounts comparable to Asian intake, the expected rise would almost certainly be clinically irrelevant. Although there is a need for long-term research, on the basis of the existing data there is no reason for individuals with gout or at risk of developing gout to avoid soyfoods.

25 Review Inflammasome and IL-1beta-mediated disorders. 2010

Hoffman, Hal M / Wanderer, Alan A. ·Division of Allergy and Immunology, University of California at San Diego and Rady Children's Hospital of San Diego, La Jolla, CA 92093, USA. hahoffman@ucsd.edu ·Curr Allergy Asthma Rep · Pubmed #20425006.

ABSTRACT: The NLRP3 inflammasome is an intracellular complex that regulates the release of proinflammatory cytokines such as interleukin-1beta in response to exogenous pathogens and endogenous danger signals. Evidence from studies involving human genetics, human ex vivo mononuclear cell responses, and in vivo and in vitro murine models confirms the importance of the inflammasome and interleukin-1beta in the pathogenesis of several inherited and complex diseases. The availability of several effective interleukin-1beta targeted therapies has allowed for successful proof-of-concept studies in several of these disorders. However, many other diseases are likely to be mediated by the inflammasome and interleukin-1beta, providing additional targets in the future.

Next